Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NYSE:ISR

Isoray (ISR) Stock Price, News & Analysis

Isoray logo

About Isoray Stock (NYSE:ISR)

Key Stats

Today's Range
N/A
50-Day Range
$0.28
$0.42
52-Week Range
N/A
Volume
145,000 shs
Average Volume
290,697 shs
Market Capitalization
$54.57 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

IsoRay, Inc. is a medical technology company, which engages in the development, manufacture, and sale of isotope-based medical products and devices. The firm focuses on the treatment of cancer and other malignant diseases. Its core product is Cesium-131, a radioisotope for the treatment of malignant tumors. The company was founded by Lance A. Bray in 1983 and is headquartered in Richland, WA.

Receive ISR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Isoray and its competitors with MarketBeat's FREE daily newsletter.

ISR Stock News Headlines

French ISR Label Revamp Report
Why IsoRay (ISR) Is Plunging Today
10 EV Stocks to Buy Right Now
EV stocks are red hot. We’ve found TEN that we think will produce big wins for early investors. There’s no charge to view this report, so I urge everyone to check out the 10 stocks we’ve found as soon as possible.
Why IsoRay (ISR) Stock Is Surging Today
IsoRay (ISR) Reports Q2 Loss, Misses Revenue Estimates
See More Headlines

ISR Stock Analysis - Frequently Asked Questions

Isoray, Inc. (NYSE:ISR) announced its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.02) earnings per share for the quarter, missing analysts' consensus estimates of ($0.01) by $0.01. The business earned $2.56 million during the quarter, compared to analyst estimates of $2.58 million. Isoray had a negative net margin of 115.91% and a negative trailing twelve-month return on equity of 17.12%.

Based on aggregate information from My MarketBeat watchlists, some other companies that Isoray investors own include Brainstorm Cell Therapeutics (BCLI), OPKO Health (OPK), Tesla (TSLA), Meta Platforms (META), Palantir Technologies (PLTR), Tonix Pharmaceuticals (TNXP) and Nano Dimension (NNDM).

Company Calendar

Last Earnings
11/10/2021
Today
11/04/2024
Fiscal Year End
6/30/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
N/A
Employees
N/A
Year Founded
N/A

Profitability

Net Income
$-7,270,000.00
Net Margins
-115.91%
Pretax Margin
-91.45%

Debt

Sales & Book Value

Annual Sales
$10.80 million
Book Value
$0.43 per share

Miscellaneous

Free Float
138,674,000
Market Cap
$54.57 million
Optionable
Not Optionable
Beta
1.48
The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

This page (NYSE:ISR) was last updated on 11/4/2024 by MarketBeat.com Staff
From Our Partners